Cargando…

Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma

epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Cuilan, Liang, Ting, Wu, Qihui, Zhou, Zheyi, Zhang, Mingmin, Feng, Dongshan, Tao, Jingrui, Si, Tao, Cai, Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791079/
https://www.ncbi.nlm.nih.gov/pubmed/36578460
http://dx.doi.org/10.1155/2022/2940654
_version_ 1784859320027971584
author Chen, Cuilan
Liang, Ting
Wu, Qihui
Zhou, Zheyi
Zhang, Mingmin
Feng, Dongshan
Tao, Jingrui
Si, Tao
Cai, Min
author_facet Chen, Cuilan
Liang, Ting
Wu, Qihui
Zhou, Zheyi
Zhang, Mingmin
Feng, Dongshan
Tao, Jingrui
Si, Tao
Cai, Min
author_sort Chen, Cuilan
collection PubMed
description epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC symptoms. However, due to its biological effects and complex compositions, its underlying mechanism of actions (MOAs) have not been fully clarified yet. In this study, we proposed a pharmacological framework to systematically explore the MOAs of RGLD against HCC. We firstly integrated the active ingredients and potential targets of RGLD. We next highlighted 25 key targets that played vital roles in both RGLD and HCC disease via a protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, an ingredient-target network of RGLD consisting of 216 ingredients with 306 targets was constructed, and multilevel systems pharmacology analyses indicated that RGLD could act on multiple biological processes related to the pathogenesis of HCC, such as cellular response to hypoxia and cell proliferation. Additionally, integrated pathway analysis of RGLD uncovered that RGLD might treat HCC through regulating various pathways, including MAPK signaling pathway, PI3K/Akt signaling pathway, TNF signaling pathway, and ERBB signaling pathway. Survival analysis results showed that HCC patients with low expression of VEGFA, HIF1A, CASP8, and TOP2A were related with a higher survival rate than those with high expression, indicating the potential clinical significance for HCC. Finally, molecular docking results of core ingredients and targets further proved the feasibility of RGLD in the treatment of HCC. Overall, this study indicates that RGLD may treat HCC through multiple mechanisms, which also provides a potential paradigm to investigate the MOAs of TCM prescription.
format Online
Article
Text
id pubmed-9791079
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Hindawi
record_format MEDLINE/PubMed
spelling pubmed-97910792022-12-27 Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma Chen, Cuilan Liang, Ting Wu, Qihui Zhou, Zheyi Zhang, Mingmin Feng, Dongshan Tao, Jingrui Si, Tao Cai, Min Comput Math Methods Med Research Article epatocellular carcinoma (HCC) is one of the leading contributors to cancer mortality worldwide. Currently, the prevention and treatment of HCC remains a major challenge. As a traditional Chinese medicine (TCM) formula, Ruangan Lidan decoction (RGLD) has been proved to own the effect of relieving HCC symptoms. However, due to its biological effects and complex compositions, its underlying mechanism of actions (MOAs) have not been fully clarified yet. In this study, we proposed a pharmacological framework to systematically explore the MOAs of RGLD against HCC. We firstly integrated the active ingredients and potential targets of RGLD. We next highlighted 25 key targets that played vital roles in both RGLD and HCC disease via a protein-protein interaction (PPI) network and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Furthermore, an ingredient-target network of RGLD consisting of 216 ingredients with 306 targets was constructed, and multilevel systems pharmacology analyses indicated that RGLD could act on multiple biological processes related to the pathogenesis of HCC, such as cellular response to hypoxia and cell proliferation. Additionally, integrated pathway analysis of RGLD uncovered that RGLD might treat HCC through regulating various pathways, including MAPK signaling pathway, PI3K/Akt signaling pathway, TNF signaling pathway, and ERBB signaling pathway. Survival analysis results showed that HCC patients with low expression of VEGFA, HIF1A, CASP8, and TOP2A were related with a higher survival rate than those with high expression, indicating the potential clinical significance for HCC. Finally, molecular docking results of core ingredients and targets further proved the feasibility of RGLD in the treatment of HCC. Overall, this study indicates that RGLD may treat HCC through multiple mechanisms, which also provides a potential paradigm to investigate the MOAs of TCM prescription. Hindawi 2022-12-17 /pmc/articles/PMC9791079/ /pubmed/36578460 http://dx.doi.org/10.1155/2022/2940654 Text en Copyright © 2022 Cuilan Chen et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Chen, Cuilan
Liang, Ting
Wu, Qihui
Zhou, Zheyi
Zhang, Mingmin
Feng, Dongshan
Tao, Jingrui
Si, Tao
Cai, Min
Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title_full Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title_fullStr Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title_full_unstemmed Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title_short Systems Pharmacology-Based Strategy to Investigate the Mechanism of Ruangan Lidan Decoction for Treatment of Hepatocellular Carcinoma
title_sort systems pharmacology-based strategy to investigate the mechanism of ruangan lidan decoction for treatment of hepatocellular carcinoma
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9791079/
https://www.ncbi.nlm.nih.gov/pubmed/36578460
http://dx.doi.org/10.1155/2022/2940654
work_keys_str_mv AT chencuilan systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT liangting systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT wuqihui systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT zhouzheyi systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT zhangmingmin systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT fengdongshan systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT taojingrui systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT sitao systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma
AT caimin systemspharmacologybasedstrategytoinvestigatethemechanismofruanganlidandecoctionfortreatmentofhepatocellularcarcinoma